Conmed Corp Dossier - Source-backed chat

Conmed Corp

CNMDNYSE

SectorHealth Care

IndustryMedical Devices

Beta (adjusted)0.94

Intrinsic Value $58.83median of 5 methods · middle span $40-$76based on filings through 30 Jun 2026

Market Price $45.93Price as of 1 Oct 2026

UndervaluedIntrinsic value is 28% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $1.4B

Enterprise Value $2B

Shares Outstanding 30.4M diluted

Moat Rating None

Next Earnings Date28 Oct 2026

Last ex-dividend15 Sep 2025

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

CONMED is undergoing a significant strategic transformation, highlighted by its deliberate exit from the lower-margin gastroenterology (GI) product portfolio to double down on high-growth, high-margin platforms like AirSeal, Buffalo Filter, and BioBrace. While this portfolio simplification is expected to expand long-term gross margins by 80 basis points, near-term performance is heavily pressured by the loss of GI revenue and substantial refinancing headwinds. Replacing its upcoming 2.25% convertible notes with traditional bank debt is projected to create at least a $0.10 EPS headwind in 2026. Consequently, while the underlying business remains fundamentally sound with raised organic growth guidance, near-term earnings pressure warrants a Hold rating.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$43.00

Mean target$45.50

High · most bullish analyst$49.00

Street targets sit below today's price; our intrinsic value sits above it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$43.0015%

The bear case is triggered by prolonged integration disruptions, slower-than-expected adoption of BioBrace, or escalating tariff and financing costs. If leverage remains elevated above 3.1x EBITDA and interest expenses rise further, adjusted EPS could fall below the guided $4.30 floor, leading to multiple compression.

Base CaseCentral scenario

$45.5060%

Matches the consensus mean

The base case assumes CONMED successfully executes its GI exit, delivering full-year 2026 reported revenue of $1.350 billion to $1.375 billion and organic constant currency growth of 5.0% to 6.5%. Adjusted EPS lands within the guided range of $4.30 to $4.45, as stronger underlying operating performance is offset by the expected $0.10 interest expense headwind from debt refinancing.

Bull CaseUpside scenario

$49.0025%

The bull case centers on rapid market adoption of CONMED's high-margin platforms (AirSeal, Buffalo Filter, and BioBrace) in Ambulatory Surgery Centers (ASCs) and robotic surgery suites. If organic constant currency growth exceeds the high end of the 5.0% to 6.5% guidance, and supply chain efficiencies materialize faster than expected, gross margin expansion could exceed 100 basis points, offsetting refinancing headwinds.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strategic shift to high-margin, high-growth platforms (AirSeal, Buffalo Filter, BioBrace) expected to improve long-term gross margin profile by 80 bps.
Strong organic constant currency growth momentum, with full-year 2026 guidance raised to 5.0%-6.5%.
Differentiated product portfolio with high switching costs and strong IP protection (1,000+ patents).

Key Investment Risks

Refinancing of upcoming convertible debt creates a material interest expense headwind of at least $0.10 per share in 2026.
Near-term revenue and earnings pressure from the accelerated exit of the gastroenterology business.
Stiff competition from larger medical device players with greater scale and commercial resources.

Thesis Invalidation Triggers

Adjusted diluted EPS falling below the guided floor of $4.30 for fiscal year 2026.
Organic constant currency revenue growth decelerating below 5.0%.
Leverage ratio failing to drop below 3.0x EBITDA due to weak operating cash flow generation.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.